[Effect of tazanolast on platelet activating factor-induced airway hyperresponsiveness in guinea pigs].
To determine whether tazanolast inhibits airway hyperresponsiveness, we studied the effect of this drug on platelet activating factor (PAF)-induced airway hyperresponsiveness in guinea pigs. Inhalation of PAF (1 microgram/ml) caused significant airway hyperresponsiveness to acetylcholine (p < 0.01) or histamine (p < 0.05). Pretreatment with tazanolast (30-300 mg/kg) produced a dose-dependent inhibition of airway hyperresponsiveness induced by PAF inhalation, and significant inhibition (p < 0.05) was obtained with the drug (300 mg/kg). Aspirin also inhibited PAF-induced airway hyperresponsiveness, while tranilast produced hardly any inhibition. From these results, it is suggested that tazanolast is effective in inhibiting airway hyperresponsiveness.
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D016535:Bronchial Hyperreactivity / Q000139:chemically induced / Q000188:drug therapy*; D006168:Guinea Pigs; D006633:Histamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D010972:Platelet Activating Factor / Q000009:adverse effects; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D062367:ortho-Aminobenzoates / Q000494:pharmacology
D006633:Histamine Antagonists; D010972:Platelet Activating Factor; D013777:Tetrazoles; C036097:butyl 3-(1H-tetrazol-5-yl)oxanilate; D062367:ortho-Aminobenzoates; C012293:tranilast; D001241:Aspirin